[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100654762":3},{"organization":4,"outcomesModule":7,"designInfo":81,"detailedDescription":88,"studyPopulation":80,"armGroups":89,"interventions":96,"overallOfficials":102,"centralContacts":110,"locations":118,"responsibleParty":131,"collaborators":80,"id":135,"slug":136,"hasResults":137,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":80,"eligibilityCriteria":141,"healthyVolunteers":137,"sex":142,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":80,"studyType":148,"phases":149,"briefSummary":150,"conditions":151,"keywords":157,"overallStatus":161,"whyStopped":80,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":171},{"fullName":5,"class":6},"University of Zurich","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":80},[9],{"measure":10,"description":11,"timeFrame":12},"Pulmonary resistance (sPAP\u002FCO) after re-ascent to 2850m","Difference in sPAP\u002FCO by echocardiography between sea level (after one-week stay) and day after re-ascent at 2850m in patients with pulmonary arterial hypertension","From Day 5-7 at sea level to day after re-ascent",[14,17,21,24,27,30,33,37,40,43,46,50,53,56,59,62,65,68,71,74,77],{"measure":15,"description":16,"timeFrame":12},"Tricuspid regurgitation velocity TRV after re-ascent to 2850m","Difference\u002Fchange in tricuspid regurgitation velocity TRV between sea level (after one-week stay) and day after re-ascent at 2850m in patients with pulmonary arterial hypertension",{"measure":18,"description":19,"timeFrame":20},"Cardiac output CO after re-ascent to 2850m","Difference\u002Fchange in cardiac output CO between sea level (after one-week stay) and Day after re-ascent to 2850m in patients with pulmonary arterial hypertension","From Day 5-7 at sea level to the day after re-ascent",{"measure":22,"description":23,"timeFrame":12},"Tricuspid annular plan systolic excursion TAPSE after re-ascent to 2850m","Difference\u002Fchange in tricuspid annular plan systolic excursion TAPSE between sea level (after one-week stay) and Day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":25,"description":26,"timeFrame":12},"Right ventricular strain after re-ascent to 2850m","Difference\u002Fchange in right ventricular strain between sea level (after one-week stay) and Day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":28,"description":29,"timeFrame":12},"Right atrial pressure RAP after re-ascent to 2850m","Difference\u002Fchange in right atrial pressure RAP between sea level (after one-week stay) and Day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":31,"description":32,"timeFrame":12},"Fractional area change FAC after re-ascent to 2850m","Difference\u002Fchange in fractional area change FAC between sea level (after one-week stay) and Day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":34,"description":35,"timeFrame":36},"PaO2 after re-ascent to 2850m","Difference\u002Fchange in PaO2 (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in patients with pulmonary arterial hypertension","From Day 7 at sea level to day after re-ascent (time frame of 3 days)",{"measure":38,"description":39,"timeFrame":36},"PaCO2 after re-ascent to 2850m","Difference\u002Fchange in PaCO2 (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":41,"description":42,"timeFrame":36},"Hemoglobin after re-ascent to 2850m","Difference\u002Fchange in hemoglobin (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":44,"description":45,"timeFrame":36},"pH after re-ascent to 2850m","Difference\u002Fchange in pH (arterial blood gas analysis) between sea level (after one-week stay) and day after re-ascent to 2850m in patients with pulmonary arterial hypertension",{"measure":47,"description":48,"timeFrame":49},"Pulmonary resistance (sPAP\u002FCO) pre-descent to after re-ascent","Difference\u002Fchange in pulmonary resistance (sPAP\u002FCO) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension","Baseline at 2850m followed by a one-week stay at sea level to the day after re-ascent back to 2850m (time frame approximately 11 days)",{"measure":51,"description":52,"timeFrame":49},"Tricuspid regurgitation velocity TRV pre-descent to after re-ascent","Difference\u002Fchange in tricuspid regurgitation velocity TRV at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":54,"description":55,"timeFrame":49},"Cardiac output CO pre-descent to after re-ascent","Difference\u002Fchange in cardiac output CO at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":57,"description":58,"timeFrame":49},"Tricuspid annular plan systolic excursion TAPSE pre-descent to after re-ascent","Difference\u002Fchange in tricuspid annular plan systolic excursion TAPSE at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":60,"description":61,"timeFrame":49},"Right ventricular strain pre-descent to after re-ascent","Difference\u002Fchange in right ventricular strain at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":63,"description":64,"timeFrame":49},"Right atrial pressure RAP pre-descent to after re-ascent","Difference\u002Fchange in right atrial pressure RAP at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":66,"description":67,"timeFrame":49},"Fractional area change FAC pre-descent to after re-ascent","Difference\u002Fchange in fractional area change FAC at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":69,"description":70,"timeFrame":49},"PaO2 pre-descent to after re-ascent","Difference\u002Fchange in PaO2 (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":72,"description":73,"timeFrame":49},"PaCO2 pre-descent to after re-ascent","Difference\u002Fchange in PaCO2 (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":75,"description":76,"timeFrame":49},"Hemoglobin pre-descent to after re-ascent","Difference\u002Fchange in hemoglobin (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",{"measure":78,"description":79,"timeFrame":49},"pH pre-descent to after re-ascent","Difference\u002Fchange in pH (arterial blood gas analysis) at 2850m with a one-week stay at sea level in between (day pre-descent vs. day after re-ascent) in patients with pulmonary arterial hypertension",null,{"allocation":82,"interventionModel":83,"interventionModelDescription":84,"primaryPurpose":85,"observationalModel":80,"timePerspective":80,"maskingInfo":86},"NA","SINGLE_GROUP","Patients diagnosed with pulmonary arterial hypertension living permanently \\> 2600m around Quito (Ecuador) will be assessed after 7 days at sea level and after re-ascent to 2850m","SUPPORTIVE_CARE",{"masking":87,"maskingDescription":80,"whoMasked":80},"NONE","The aim of this research is to investigate the pulmonary resistance (sPAP\u002FCO) by echocardiography and other hemodynamic outcomes before and after re-ascent (sea level for 7 days vs. re-ascent to 2850m) in patients with diagnosed pulmonary arterial hypertension according to guidelines, who permanently live at high altitude over 2600m",[90],{"label":91,"type":92,"description":93,"interventionNames":94},"Pulmonary resistance (sPAP\u002FCO) at sea level and after re-ascent at 2850m","EXPERIMENTAL","Assessment of pulmonary resistance (sPAP\u002FCO) and other hemodynamic parameters after 7 days at sea level with re-ascent from sea level back to 2850m by bus (in one day) and assessment of the same outcomes",[95],"Behavioral: Re-Ascent from sea level to 2850m",[97],{"type":98,"name":99,"description":100,"armGroupLabels":101,"otherNames":80},"BEHAVIORAL","Re-Ascent from sea level to 2850m","After 7 days at sea level return\u002Fre-ascent to their usual living altitude at 2850m",[91],[103,107],{"name":104,"affiliation":105,"role":106},"Silvia Ulrich","University Hospital Zurich, Departement of Pulmonology","PRINCIPAL_INVESTIGATOR",{"name":108,"affiliation":109,"role":106},"Rodrigo Hoyos","Hospital Carlos Andrade Marin of Quito, Ecuador",[111,116],{"name":112,"role":113,"phone":114,"phoneExt":80,"email":115},"Silvia Ulrich, Prof. Dr. med.","CONTACT","+41442552220","silvia.ulrich@usz.ch",{"name":117,"role":113,"phone":114,"phoneExt":80,"email":80},"Michael Furian, Prof. Dr. sc. ETH",[119],{"facility":120,"status":80,"city":121,"state":80,"zip":122,"country":123,"countryCode":124,"cosmosGeoPoint":125,"geoPoint":130,"contacts":80},"University Hospital of Zurich","Zurich","8091","Switzerland","CH",{"type":126,"coordinates":127},"Point",[128,129],8.55,47.36667,{"lat":129,"lon":128},{"type":132,"investigatorFullName":133,"investigatorTitle":134,"investigatorAffiliation":5,"oldNameTitle":80,"oldOrganization":80},"SPONSOR_INVESTIGATOR","Silvia Ulrich Somaini","Prof. Dr. med.","100654762","assessment-of-total-pulmonary-resistance-spapco-between-sea-level-la-vs-high-altitude-ha-after-re-ascent-in-patients-with-pulmonary-arterial-hypertension-pah-100654762",false,"NCT07804693","Assessment of Total Pulmonary Resistance sPAP\u002FCO Between Sea Level LA vs. High Altitude HA After Re-ascent in Patients With Pulmonary Arterial Hypertension PAH","Effect of a One-week Descent From 2850m to Sea Level and Re-ascent in Patients With Pulmonary Arterial Hypertension and Healthy Controls Permanently Living > 2600m on Pulmonary Hemodynamics, Exercise Capacity, Blood Oxygenation, Sleep Disordered Breathing and Further Outcomes","Inclusion Criteria:\n\n* Adult patients aged 18-80 years and of all genders\n* Permanent residence \\> 2600 m\n* Diagnosis of pulmonary arterial hypertension PAH (PAHHA-Group) according to guidelines\n* Patients are stable on therapy\n* NYHA (new york heart association) functional class I-III.\n* written informed consent to participate in the study.\n\nExclusion Criteria:\n\n* Age \\\u003C18 years or \\>80 years\n* unstable condition\n* Patients who cannot follow the study investigations\n* Patient permanently living \\\u003C 2600m.\n* Patients who traveled and stayed overnight at altitudes \\\u003C2000 m in the past 4 weeks.\n* Patients with moderate to severe concomitant lung disease (FEV1\\\u003C70% or forced vital capacity \\\u003C70%), severe parenchymal lung disease, severe smokers (\\>20 cigarettes\u002Fday)\n* Severely hypoxemic patients at Quito permanently having persistent SpO2 (oxygen saturation by pulseoximetry) \\\u003C80% on ambient air.\n* Patient with a non-corrected ventricular septum defect\n* Relevant concomitant other disease of the heart, kidney, liver, blood (anemia hemoglobin\\\u003C11 g\u002Fdl)","ALL","18 Years","80 Years",{"count":146,"type":147},20,"ESTIMATED","INTERVENTIONAL",[82],"To study the effect of a re-ascent after a one-week stay at sea level (after prior descent from 2850m) to high altitude (Quito Ecuador: 2850m) on pulmonary resistance (sPAP\u002FCO) and other hemodynamic outcomes in patients with pulmonary arterial hypertension PAH, who live permanently \\>2600m.",[152,153,154,155,156],"Pulmonary Arterial Hypertension (PAH)","Pulmonary Vascular Disease","High Altitude","Echocardiography","Pulmonary Resistance",[152,158,154,159,156,155,160],"Hypoxia","Pulmonary Hypertension","hemodynamics","NOT_YET_RECRUITING","2026-08-31",{"date":164,"type":165},"2026-09-04","ACTUAL",{"date":167,"type":147},"2026-09-25",{"date":169,"type":147},"2026-12-31",{"name":133,"class":6},1]